Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

The Effect of Sleep on Tendon Cellular Adaptation (TSS)

5 november 2026 bijgewerkt door: Daniel Moore, University of Toronto

The Effect of Sleep on Human Tendon Cellular Remodeling: a ex Vivo Pilot Study.

The goal of this observational study is to evaluate the effect of hormones which surge or diminish during different stages of sleep on collagen turnover in tendon cells. The main questions it aims to answer are:

  1. To evaluate the effect of serum taken from participants overnight on human tendon cell-derived collagen expression in a cell culture model.
  2. To evaluate whether tendon cell-derived collagen expression in a cell culture model is driven by changes in collagen synthesis or breakdown.

To evaluate the effect of sleep on tendon adaptation, blood will be taken from human participants overnight and used to treat a tendon cell culture model.

Studie Overzicht

Toestand

Werving

Conditie

Gedetailleerde beschrijving

Recent clinical evidence has linked poor sleep with increased risk of musculoskeletal injury while evidence from basic biological models indicates that growth hormone and cortisol may regulate the turnover of collagen, a key structural protein in tendons. Growth hormone concentration in the blood surges during deep sleep (~1-2 hr after sleep onset), while cortisol concentration reaches a nadir at this same time. It remains unclear whether serum containing these hormones, collected during sleep itself, can modulate collagen turnover processes. Therefore, the purpose of this study is to evaluate the effect of hormones which surge or diminish during different stages of sleep on collagen turnover in tendon cells.

This study will use a within-subjects design to collect serum for ex vivo experiments. The total study duration will be ~8 days. Participants will first be screened to ensure compliance with our inclusion and exclusion criteria. Written informed consent will be obtained from participants that pass screening. Twelve participants will be recruited in total (6 male, 6 female). Participants will complete a 7 night sleep diary while wearing two wearable devices (an accelerometer to measure physical activity and basic sleep outcomes, worn on the waist; a Fitbit to estimate sleep stages and sleep onset). After the sleep diary, participants will arrive at the laboratory following an overnight fast for a resting venous blood collection. They will return to the laboratory to sleep overnight in the Nutrition and Metabolism Research Group's Bed Rest Facility. Approximately 95 minutes following sleep onset, participants will be briefly awoken for a venous blood draw (i.e., deep sleep sample), before returning to sleep. Four hours after the deep sleep sample, participants will be briefly woken up for a venous blood draw (i.e., REM sleep sample). Participants will then be allowed to finish their night of sleep in the facility.

Commercially available human tenocytes will be treated with serum from the different timepoints (morning, deep/early sleep, REM/late sleep) for 7 days. Following the 7 day treatment period, tenocytes will be collected and collagen I and III expression will be assessed by immunoblot while stable isotope tracers will be used to quantify collagen synthesis and breakdown.

The primary objective of the study is to evaluate the effect of the nocturnal biochemical milieu on human tenocyte-derived collagen expression in vitro. The secondary objectives of the study is to assess whether changes in collagen expression are due to altered collagen synthesis and/or breakdown.

Studietype

Observationeel

Inschrijving (Geschat)

12

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

  • Canada
    • Ontario
      • Kingston, Ontario, Canada, K7L 3N6
        • Werving
        • School of Kinesiology and Health Studies Building
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 35 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Resident of Kingston, Ontario

Beschrijving

Inclusion Criteria:

  • healthy (determined using a medical screening questionnaire)
  • between the ages of 18 and 35
  • participants must be a non-smoker
  • self-reported moderately active (>150 minutes of moderate-to-vigorous physical activity per week)
  • self-reported weight stable (< 2 kg increase or decrease in weight over the previous 6 months)
  • sleep ≥ 7 hours per night
  • female participants must have a stable menstrual cycle (>3 months of 21-35 day cycle length).

Exclusion Criteria:

  • have a BMI <18.5 or >29.9 kg/m2
  • have a history of clinically diagnosed insomnia (>7 on the Insomnia Severity Index) or other sleep disorder (e.g., sleep apnea)
  • use a hormonal contraceptive (oral or IUD)
  • consume 7+ standard drinks per week (high risk range)
  • use cannabis >1 time per week
  • have any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the investigators, would compromise the ability to comply with the study requirements
  • regularly use anti-inflammatory and/or analgesic medication, whether prescription or not; use any medications known to affect collagen metabolism (e.g., glucocorticoids, acetaminophen, non-steroidal anti-inflammatory medication, or prescription strength acne medication, ACE inhibitors, proton pump inhibitors, growth hormone, GLP-1 receptor agonists);
  • participated in a study involving a phenylalanine stable-isotope tracer in the previous year

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Healthy, young males and females.

Healthy, recreationally active, young adults (18-35) regularly getting > 7 h of sleep per night are the target population. There is no intervention for this study.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Collagen Expression
Tijdsspanne: Ex vivo experiments and immunoblot analysis will conclude approximately 12 weeks following serum collection.

Tenocyte-derived collagen expression will be assessed following a 7 day treatment period using daytime, early/deep sleep, and late/REM sleep by immunoblot.
Ex vivo experiments and immunoblot analysis will conclude approximately 12 weeks following serum collection.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Collagen Synthesis
Tijdsspanne: Ex vivo experiments and immunoblot analysis will conclude approximately 12 weeks following serum collection.

On the last day of the 7 day serum incubation, cells will be treated with a stable-isotope tracer for 6hrs to measure incorporation of this tracer into tenocyte collagen and thus collagen synthesis.
Ex vivo experiments and immunoblot analysis will conclude approximately 12 weeks following serum collection.
Collagen breakdown
Tijdsspanne: Ex vivo experiments and immunoblot analysis will conclude approximately 12 weeks following serum collection.

Cells will be treated with a stable isotope tracer during a 7 day serum incubation. Six hours prior to collection, tracer will be withdrawn and tracer release into the media will be measured to estimate collagen breakdown.
Ex vivo experiments and immunoblot analysis will conclude approximately 12 weeks following serum collection.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

University of Toronto

Medewerkers

Tanenbaum Institute for Science in Sport

Onderzoekers

  • Hoofdonderzoeker: Chris McGlory, PhD, Queen's University
  • Hoofdonderzoeker: Dan R Moore, PhD, University of Toronto

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

10 november 2026

Primaire voltooiing (Geschat)

1 februari 2027

Studie voltooiing (Geschat)

1 mei 2027

Studieregistratiedata

Eerst ingediend

5 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

5 november 2026

Eerst geplaatst (Werkelijk)

12 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 november 2026

Laatste update ingediend die voldeed aan QC-criteria

5 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Andere studie-ID-nummers

  • TSS
  • TISS FKPE Seed Grant (Ander subsidie-/financieringsnummer: Tanenbaum Institute for Science in Sport)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

This study is a collaboration between the McGlory and Moore research groups. Therefore, sleep and activity data will be shared between groups. Serum collected from sleep trials at the McGlory lab will also be shared with the Moore lab where ex vivo experiments will be conducted. However, no identifying information collected by the McGlory lab will be shared with the Moore lab.

IPD-tijdsbestek voor delen

IPD collected by the McGlory lab will be made available to collaborators at the Moore lab following completion of data collection (estimated October 2026) until the time of publication (estimated November 2027).

IPD-toegangscriteria voor delen

Paul Babits and Dr. Daniel Moore will have access sleep, activity data as well as serum collected during overnight trials. Electronic data will be shared via secure servers. Serum will be shipped between sites following the completion of data collection.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren